Merck & CompanyvsSAB Biotherapeutics

MRK and SABS stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

SABS

SAB Biotherapeutics, Inc.

$2.81

Value $253M

-3.44%
SABS's page

Merck & Company (MRK) has a market value of $331B and SAB Biotherapeutics (SABS) $253M. Over the last year, with dividends, MRK moved +44.8% and SABS -26.6%. Dividend yield: MRK 2.54%, SABS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$331B

    SABS$253M

    MRK is 1,306 times SABS

  • Revenue, 12 months

    MRK$67.4B

    SABS$0

  • Net income, 12 months

    MRK$2.5B

    SABS-$81M

  • Operating margin

    MRK–

    SABS–

  • ROIC

    MRK3.9%

    SABS-25.5%

    29.4 points apart

  • P/E

    MRK134.8

    SABS–

  • Dividend yield

    MRK2.5%

    SABS0.0%

    2.5 points apart

  • 5-year return

    MRK+93.0%

    SABS-97.5%

    190.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+93.0%

SABS-97.5%

010020020222023202420252026
Returns by period
PeriodMRKWith dividendsSABSWith dividends
1 year since November 19, 2025+44.8%Price +40.7%-26.6%Price -26.6%
3 years since November 20, 2023+42.7%+12.6% a yearPrice +30.2%-66.3%-30.4% a yearPrice -66.3%
5 years since November 19, 2021+93.0%+14.1% a yearPrice +65.7%-97.5%-52.0% a yearPrice -97.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanySABSSAB Biotherapeutics

Valuation

MRKSABS
Valuation
Price$133.72$2.81
Market value$331B$253M
Enterprise value (EV)$375B$152M
P/E134.8–
P/E, 5-year median14.8–
P/B7.41.2
EV/EBIT78.7–
Free cash flow yield4.5%–

Results and growth

MRKSABS
Results and growth
Revenue, 12 months$67.4B$0
Net income, 12 months$2.5B-$81M
Free cash flow, 12 months$14.7B-$46M
Earnings per share, 12 months$0.98-$1.33
Revenue growth, year on year1.3%-100.0%
Revenue growth a year, past+9.4%over 5 years–
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKSABS
Margins and returns on capital
Gross margin71.8%–
Operating margin––
Net margin3.6%–
ROIC3.9%-25.5%
ROE5.2%-41.5%

Balance sheet

MRKSABS
Balance sheet
Cash$9.7B$104M
Total debt$53.8B$4.9M
Net debt / EBITDA5.7–
Interest cover2.4×-211.2×

Dividends and buybacks

MRKSABS
Dividends and buybacks
Dividend yield2.5%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.5%–
Shareholder yield4.1%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or SABS

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or SAB Biotherapeutics?

By market value, Merck & Company ($331B) is about 1,306.0 times SAB Biotherapeutics ($253M), at today's prices.

How did MRK and SABS stock do over the last 5 years?

Since November 19, 2021, MRK's price moved +65.7% and SABS's -97.5%. With dividends: MRK +93.0% (+14.1% a year), SABS -97.5% (-52.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or SABS?

The dividend yield at today's price is 2.54% for Merck & Company and none for SAB Biotherapeutics. Over the last twelve months they paid $3.40 and – per share.

Which is the better investment, Merck & Company or SAB Biotherapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.